Hydroxychloroquine Market Intelligence

best-value

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)

feature

 No Additional Benefits

Subscription Benefits:

  • PRO access to New Beroe LiVE*
  • Unlimited updates on the Report*
  • Supplier Watchlist for 3 suppliers*
  • Supplier Shortlisting Tool*

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)

feature

*These features will be unlocked on the new Beroe LiVE when it launches (Q3, 2020)

Are you looking for answers on Hydroxychloroquine category?

Are you looking for answers on Hydroxychloroquine category?

  • What are the key trends in Hydroxychloroquine category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in Hydroxychloroquine industry?
  • How is Hydroxychloroquine industry performing?

Over 50,000+ users trust Beroe

Report Coverage

  1. Market Analysis
  2. Market Overview – Hydroxychloroquine
  3. Value Chain Analysis
  4. Price Analysis

Table of Contents

  1. Executive Summary
  2. Market Overview
  3. COVID-19 Impact
  4. Cost Analysis
  1. Market Analysis
  2. Market Dynamics & Impact Assessment – Outlook on API and Intermediates
  3. Impact of COVID-19 on API
  4. Supply Risk Evaluation & Mitigation Plan
  5. Market Overview – Hydroxychloroquine
  6. Trade Flow – Hydroxychloroquine
  7. Sourcing Practice – Hydroxychloroquine
  1. Value Chain Analysis
  2. Value Chain
  1. Price Analysis
  2. Price Analysis – HCQ
  3. Feedstock Analysis
  1. Industry Analysis
  2. Porter’s Five Forces Analysis
  1. Cost Analysis
  2. Cost Driver Analysis
  3. Cost Breakdown

Want a more detailed personalised report?

Hydroxychloroquine Global Market Outlook:

  • India has accounted for nearly 70 percent of the global production of hydroxychloroquine. Exports have increased drastically to cater to the global demand
  • Demand for Hydroxychloroquine has declined, as new drugs were invented for COVID-19, however, HCQ is always used to treat and manage a number of conditions, such as rheumatoid arthritis and the autoimmune disease called lupus
  • Raw materials account for 50–60 percent of the total cost of production
  • HNDA and 4,7 DCQ are the major raw materials driving the production cost
  • Investing in capacity expansions and equipment are key fixed costs, which are involved in manufacturing of API

Porter's Analysis on Hydroxychloroquine

Supplier Power

  • Supplier power is medium, as the market is fragmented
  • Regulated players have more power, as there are only a few regulated players catering to the regulated markets

Barriers to New Entrants

  • Availability of raw material is a major barrier to new suppliers entering the market

Intensity of Rivalry

  • Market being fragmented, the intensity of rivalry is also high
  • Competition exists among certified manufacturers to supply HCQ to the developed markets

Threat of Substitutes

  • Hydroxychloroquine, an anti-malarial drug, was initially used in the treatment of COVID-19, however, it was not very effective and had side effects
  • Several other vaccines are proving to be effective against COVID-19, hence, threat of substitute is high

Buyer Power

  • Although several manufacturers are available in the market choosing a supplier, who has DMF or CEP approved suppliers is crucial
  • Buyer power is moderate, since the number of buyers in the market is also high

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)

feature

Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.

x

COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)